Effect of melanoma stem cells on melanoma metastasis (Review)
- Authors:
- Qiliang Yin
- Xiumin Shi
- Shijie Lan
- Haofan Jin
- Di Wu
-
Affiliations: Department of Tumor Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China - Published online on: May 29, 2021 https://doi.org/10.3892/ol.2021.12827
- Article Number: 566
-
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Lo JA and Fisher DE: The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science. 46:945–949. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Holderfield M, Deuker MM, McCormick F and McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Christiansen SA, Khan S and Gibney GT: Targeted therapies in combination with immune therapies for the treatment of metastatic melanoma. Cancer J. 23:59–62. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nandy SB and Lakshmanaswamy R: Cancer stem cells and metastasis. Prog Mol Biol Transl Sci. 151:137–176. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Parmiani G: Melanoma cancer stem cells: Markers and functions. Cancers (Basel). 8:342016. View Article : Google Scholar : PubMed/NCBI | |
|
Fink J, Andersson-Rolf A and Koo BK: Adult stem cell lineage tracing and deep tissue imaging. BMB Rep. 48:655–667. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P and Colombel M: Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate. 73:1738–1746. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Croker AK and Allan AL: Cancer stem cells: Implications for the progression and treatment of metastatic disease. J Cell Mol Med. 12:374–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Tiede B, Massague J and Kang Y: Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wickremesekera AC, Brasch HD, Lee VM, Davis PF, Woon K, Johnson R, Tan ST and Itinteang T: Expression of cancer stem cell markers in metastatic melanoma to the brain. J Clin Neurosci. 60:112–116. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen N, Couts KL, Luo Y and Fujita M: Understanding melanoma stem cells. Melanoma Manag. 2:179–188. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 20:102–107. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, et al: Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget. 6:71–84. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Marzagalli M, Raimondi M, Fontana F, Montagnani Marelli M, Moretti RM and Limonta P: Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Semin Cancer Biol. 59:221–235. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar D, Gorain M, Kundu G and Kundu GC: Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol Cancer. 16:72017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee N, Barthel SR and Schatton T: Melanoma stem cells and metastasis: Mimicking hematopoietic cell trafficking? Lab Invest. 94:13–30. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shakhova O and Sommer L: Testing the cancer stem cell hypothesis in melanoma: The clinics will tell. Cancer Lett. 338:74–81. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D, Tang DG and Rycaj K: Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol. 52:94–106. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NNV, Kumar TVS, Patil TV, Thulasiram HV and Kundu GC: Notch1-MAPK signaling axis regulates CD133(+) cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol. 136:2462–2474. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 26:3008–3017. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Houben R, Wischhusen J, Menaa F, Synwoldt P, Schrama D, Brocker EB and Becker JC: Melanoma stem cells: Targets for successful therapy? J Dtsch Dermatol Ges. 6:541–546. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lai CY, Schwartz BE and Hsu MY: CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 72:5111–5118. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmerer RM, Matthiesen P, Kreher F, Kampmann A, Spalthoff S, Jehn P, Bittermann G, Gellrich NC and Tavassol F: Putative CD133+ melanoma cancer stem cells induce initial angiogenesis in vivo. Microvasc Res. 104:46–54. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma BK, Manglik V, O'Connell M, Weeraratna A, McCarron EC, Broussard JN, Divito KA, Simbulan-Rosenthal CM, Rosenthal DS and Zapas JL: Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma. Int J Oncol. 41:1570–1576. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khattouti A, Selimovic D, Haikel Y, Megahed M, Gomez CR and Hassan M: Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer Lett. 343:123–133. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Koshio J, Kagamu H, Nozaki K, Saida Y, Tanaka T, Shoji S, Igarashi N, Miura S, Okajima M, Watanabe S, et al: DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells. Cancer Immunol Immunother. 62:1619–1628. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gedye C, Quirk J, Browning J, Svobodova S, John T, Sluka P, Dunbar PR, Corbeil D, Cebon J and Davis ID: Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother. 58:1635–1646. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lang D, Mascarenhas JB and Shea CR: Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol. 31:166–178. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al: Identification of cells initiating human melanomas. Nature. 451:345–349. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Begicevic RR and Falasca M: ABC transporters in cancer stem cells: Beyond chemoresistance. Int J Mol Sci. 18:23622017. View Article : Google Scholar : PubMed/NCBI | |
|
Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W and Frank MH: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65:4320–4333. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T and Herlyn M: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Tang L, Lin J, Shen Z, Yao Y, Wang W, Tao S, Gu C, Ma J, Xie Y and Liu Y: ABCB5 promotes melanoma metastasis through enhancing NF-κB p65 protein stability. Biochem Biophys Res Commun. 492:18–26. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao J, Egger ME, McMasters KM and Hao H: Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines. BMC Cancer. 18:6752018. View Article : Google Scholar : PubMed/NCBI | |
|
de Waard NE, Kolovou PE, McGuire SP, Cao J, Frank NY, Frank MH, Jager MJ and Ksander BR: Expression of multidrug resistance transporter ABCB5 in a murine model of human conjunctival melanoma. Ocul Oncol Pathol. 1:182–189. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vasquez-Moctezuma I, Meraz-Rios MA, Villanueva-Lopez CG, Magana M, Martinez-Macias R, Sanchez-Gonzalez DJ, García-Sierra F and Herrera-González NE: ATP-binding cassette transporter ABCB5 gene is expressed with variability in malignant melanoma. Actas Dermosifiliogr. 101:341–348. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J and Frank MH: Isolation of circulating melanoma cells. Methods Mol Biol. Sep 29–2015.(Epub ahead of print). doi: https://doi.org/10.1007/7651_2015_300. View Article : Google Scholar | |
|
Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, et al: VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res. 71:1474–1485. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schatton T, Schutte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF and Frank MH: Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 70:697–708. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Eggermont AM and Robert C: New drugs in melanoma: It's a whole new world. Eur J Cancer. 47:2150–2157. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, et al: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 466:133–137. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chesa PG, Rettig WJ, Thomson TM, Old LJ and Melamed MR: Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J Histochem Cytochem. 36:383–389. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L and Mingari MC: Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol. 21:793–801. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Truzzi F, Marconi A, Lotti R, Dallaglio K, French LE, Hempstead BL and Pincelli C: Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. J Invest Dermatol. 128:2031–2040. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nielsen PS, Riber-Hansen R and Steiniche T: Immunohis tochemical CD271 expression correlates with melanoma progress in a case-control study. Pathology. 50:402–410. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo R, Fierro-Fine A, Goddard L, Russell M, Chen J, Liu CZ, Fung KM and Hassell LA: Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain. Int J Clin Exp Pathol. 7:8947–8951. 2014.PubMed/NCBI | |
|
Denkins Y, Reiland J, Roy M, Sinnappah-Kang ND, Galjour J, Murry BP, Blust J, Aucoin R and Marchetti D: Brain metastases in melanoma: Roles of neurotrophins. Neuro Oncol. 6:154–165. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, et al: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 546:431–435. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Holzel M and Tuting T: Inflammation-induced plasticity in melanoma therapy and metastasis. Trends Immunol. 37:364–374. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R and Sommer L: low neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nat Commun. 8:19882017. View Article : Google Scholar : PubMed/NCBI | |
|
Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R and Regenbrecht CR: The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One. 9:e925962014. View Article : Google Scholar : PubMed/NCBI | |
|
Prasmickaite L, Skrbo N, Hoifodt HK, Suo Z, Engebraten O, Gullestad HP, Aamdal S, Fodstad Ø and Maelandsmo GM: Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res. 23:449–451. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, et al: Increased CD271 expression by the NF-κB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discov. 1:150302015. View Article : Google Scholar : PubMed/NCBI | |
|
Schnegg CI, Yang MH, Ghosh SK and Hsu MY: Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res. 75:1682–1690. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Valyi-Nagy K, Kormos B, Ali M, Shukla D and Valyi-Nagy T: Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures. Mol Vis. 18:588–592. 2012.PubMed/NCBI | |
|
Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M and Ziman M: Circulating melanoma cell subpopulations: Their heterogeneity and differential responses to treatment. J Invest Dermatol. 135:2040–2048. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M and Sommer L: Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71:3098–3109. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Furuta J, Inozume T, Harada K and Shimada S: CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol. 134:1369–1377. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roesch A: Melanoma stem cells. J Dtsch Dermatol Ges. 13:118–124. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Clarke MF and Fuller M: Stem cells and cancer: Two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V and Bosenberg MW: Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 70:388–397. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Frank NY, Schatton T and Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest. 120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, Leong SP, Smith JE and Ghadially R: Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol. 130:2799–2808. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pinc A, Somasundaram R, Wagner C, Hormann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, et al: Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 20:1056–1062. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Akbulut H, Babahan C, Abgarmi SA, Ocal M and Besler M: Recent advances in cancer stem cell targeted therapy. Crit Rev Oncog. 24:1–20. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yaiza JM, Gloria RA, Maria Belen GO, Elena LR, Gema J, Juan Antonio M, María Ángel GC and Houria B: Melanoma cancer stem-like cells: Optimization method for culture, enrichment and maintenance. Tissue Cell. 60:48–59. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C and Abken H: Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA. 108:2474–2479. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy GF, Wilson BJ, Girouard SD, Frank NY and Frank MH: Stem cells and targeted approaches to melanoma cure. Mol Aspects Med. 39:33–49. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schlaak M, Schmidt P, Bangard C, Kurschat P, Mauch C and Abken H: Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 3:22–30. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW and Huang EH: Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 69:8208–8215. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Roudi R, Korourian A, Shariftabrizi A and Madjd Z: Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Invest. 33:294–302. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida A, Hsu LC and Dave V: Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 46:239–244. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, Thompson DC and Vasiliou V: Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med. 56:89–101. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P and Baudin B: Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics. 6:5183–5192. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR and Mohuczy D: Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther. 312:339–345. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L and Stecca B: Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 30:1808–1818. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, et al: ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 30:2100–2113. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Contador-Troca M, Alvarez-Barrientos A, Merino JM, Morales-Hernandez A, Rodriguez MI, Rey-Barroso J, Barrasa E, Cerezo-Guisado MI, Catalina-Fernández I, Sáenz-Santamaría J, et al: Dioxin receptor regulates aldehyde dehydrogenase to block melanoma tumorigenesis and metastasis. Mol Cancer. 14:1482015. View Article : Google Scholar : PubMed/NCBI | |
|
Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M and Ghadially R: Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res. 25:138–148. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Willis BC, Johnson G, Wang J and Cohen C: SOX10: A useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol. 23:109–112. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Paratore C, Goerich DE, Suter U, Wegner M and Sommer L: Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development. 128:3949–3961. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, Claudinot S, Okoniewski M, Beermann F, Mihic-Probst D, et al: Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol. 14:882–890. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Taghizadeh R, Noh M, Huh YH, Ciusani E, Sigalotti L, Maio M, Arosio B, Nicotra MR, Natali P, Sherley JL and La Porta CA: CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One. 5:e151832010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao F, Zhang R, Wang J, Wu D, Pan M, Li M, Guo M and Dou J: Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine. Int Immunopharmacol. 52:238–244. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dou J, He X, Liu Y, Wang Y, Zhao F, Wang X, Chen D, Shi F and Wang J: Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs. Cell Biol Int. 38:452–461. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Le Coz V, Zhu C, Devocelle A, Vazquez A, Boucheix C, Azzi S, Gallerne C, Eid P, Lecourt S and Giron-Michel J: IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process. Oncotarget. 7:82511–82527. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
RS K: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rafii S, Lyden D, Benezra R, Hattori K and Heissig B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2:826–835. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL and Hung SC: Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene. 32:4343–4354. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon ES, Lee IH, Heo SC, Shin SH, Choi YJ, Park JH, Park DY and Kim JH: Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim Biophys Acta. 1801:1205–1213. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S and Bhattacharya J: Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 113:4197–4205. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Zhang S, Ni C, Zhang D, Liu Y, Zhang W, Zhao X, Zhao C and Shi M: Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. Stem Cells Dev. 14:292–298. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843–7848. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bussolati B, Bruno S, Grange C, Ferrando U and Camussi G: Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 22:3696–3705. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hendrix MJ, Seftor EA, Hess AR and Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer. 3:411–421. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV and Hendrix MJ: Tumor cell vasculogenic mimicry: From controversy to therapeutic promise. Am J Pathol. 181:1115–1125. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Girouard SD and Murphy GF: Melanoma stem cells: Not rare, but well done. Lab Invest. 91:647–664. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A and Lichinitser M: VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Melanoma Res. 21:91–98. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chao OS, Chang TC, Di Bella MA, Alessandro R, Anzanello F, Rappa G, Goodman OB and Lorico A: The HDAC6 inhibitor tubacin induces release of CD133(+) extracellular vesicles from cancer cells. J Cell Biochem. 118:4414–4424. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Alamodi AA, Eshaq AM, Hassan SY, Al Hmada Y, El Jamal SM, Fothan AM, Arain OM, Hassan SL, Haikel Y, Megahed M and Hassan M: Cancer stem cell as therapeutic target for melanoma treatment. Histol Histopathol. 31:1291–1301. 2016.PubMed/NCBI | |
|
Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, et al: Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 132:2440–2450. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu B, Wang Y, Yu X, Zhang H, Zhu J, Wang C, Chen F, Liu C, Wang J and Zhu H: Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells. Int J Nanomedicine. 12:2553–2567. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shidal C, Al-Rayyan N, Yaddanapudi K and Davis KR: Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells. Oncotarget. 7:84128–84141. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kaushik G, Venugopal A, Ramamoorthy P, Standing D, Subramaniam D, Umar S, Jensen RA, Anant S and Mammen JM: Honokiol inhibits melanoma stem cells by targeting notch signaling. Mol Carcinog. 54:1710–1721. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bhattacharyya S, Mitra D, Ray S, Biswas N, Banerjee S, Majumder B, Mustafi SM and Murmu N: Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression. Microvasc Res. 121:52–62. 2019. View Article : Google Scholar : PubMed/NCBI |
